Table Info

Table 6.

90% CI for Doxo 3 and Doxo 3 + drug parametric conditions

Cases	Parametric conditions	Peak amplitude	Peak width	AUC
Doxo 3	75% ↑ in (β, γ, p₁, p₂, p₃)	[0.3373, 0.3390]	[19.2700, 19.3436]	[31.1452, 31.2368]
Doxo 3 + Pyr6	Doxo 3 + 50% ↓ in β	[0.3271, 0.3288]	[25.1828, 25.2654]	[24.9923, 25.0537]
Doxo 3 + linoleic acid	Doxo 3 + 50% ↓ in β and γ	[0.3348, 0.3365]	[24.3140, 24.3876]	[23.2118, 23.2662]
Doxo 3 + SKF96365	Doxo 3 + 50% ↓ in β and γ	[0.3348, 0.3365]	[24.3138, 24.3892]	[23.1945, 23.2495]
Doxo 3 + dantrolene	Doxo 3 + 50% ↓ in p₁	[0.2122, 0.2133]	[25.8705, 25.9780]	[26.2765, 26.3655]
Doxo 3 + caffeine	Doxo 3 + 50% ↓ in p₁	[0.2122, 0.2133]	[25.8709, 25.9809]	[26.2900, 26.3800]

↓: increase in the parameter value; ↑: decrease in the parameter value

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/100242_sup_1.pdf.

Declarations

Author contributions

GA, SG, and SC conceived and designed the study. SG performed the mathematical analysis. GA performed the numerical simulation. GA and SC interpreted the results. GA, SG, and SC contributed to the writing of the manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The work is supported by SERB (Govt. of India), grant no.: CRG/2019/005477. The work of GA is supported by THSTI PhD fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–8. [DOI] [PubMed]

Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69:313–7. [DOI] [PubMed]

Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401. [DOI] [PubMed]

Carey L, Winer E, Viale G, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Clin Oncol. 2010;7:683–92. [DOI]

Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–36. [DOI] [PubMed] [PMC]

Bianchini G, Balko JM, Mayer IA, ME Sanders, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90. [DOI] [PubMed] [PMC]

Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8:1483–507. [DOI] [PubMed] [PMC]

Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013;138:591–9. [DOI] [PubMed]

Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36:822–46. [DOI] [PubMed]

10.

Haque W, Verma V, Hatch S, Klimberg VS, Butler EB, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170:559–67. [DOI] [PubMed]

11.

Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65:157–70. [DOI] [PubMed]

12.

Varghese E, Samuel SM, Sadiq Z, Kubatka P, Liskova A, Benacka J, et al. Anti-cancer agents in proliferation and cell death: the calcium connection. Int J Mol Sci. 2019;20:3017. [DOI]

13.

Bong AH, Bassett JJ, Roberts-Thomson SJ, Monteith GR. Assessment of doxorubicin-induced remodeling of Ca²⁺ signaling and associated Ca²⁺ regulating proteins in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2020;522:532–8. [DOI] [PubMed]

14.

Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7:3–17. [DOI] [PubMed] [PMC]

15.

Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta. 2015;1848:2502–11. [DOI] [PubMed]

16.

Zhou S, Heller LJ, Wallace KB. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol. 2001;175:60–7. [DOI] [PubMed]

17.

Wallace KB. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol. 2007;7:101–7. [DOI] [PubMed]

18.

Boehmerle W, Splittgerber U, Lazarus MB, McKenzie KM, Johnston DG, Austin DJ, et al. Paclitaxel induces calcium oscillations via an inositol 1, 4, 5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci U S A. 2006;103:18356–61. [DOI] [PubMed] [PMC]

19.

Ma X, Cai Y, He D, Zou C, Zhang P, Lo CY, et al. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci U S A. 2012;109:16282–7. [DOI] [PubMed] [PMC]

20.

Abdoul-Azize S, Buquet C, Li H, Picquenot JM, Vannie JP. Integration of Ca²⁺ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Oncogene. 2018;37:4979–93. [DOI] [PubMed]

21.

AbuHammad S, Zihlif M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 2013;101:213–20. [DOI] [PubMed]

22.

Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180:2490–503. [DOI] [PubMed] [PMC]

23.

Arafa ESA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 2011;706:28–35. [DOI] [PubMed] [PMC]

24.

Motiani RK, Hyzinski-García MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch. 2013;465:1249–60. [DOI] [PubMed] [PMC]

25.

Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer cell. 2009;15:124–34. [DOI] [PubMed]

26.

Schmidt S, Liu G, Liu G, Yang W, Honisch S, Pantelakos S, et al. Enhanced Orai1 and STIM1 expression as well as store operated Ca²⁺ entry in therapy resistant ovary carcinoma cells. Oncotarget. 2014;5: 4799–810. [DOI] [PubMed] [PMC]

27.

Tang BD, Xia X, Lv XF, Yu BX, Yuan JN, Mai XY, et al. Inhibition of Orai1-mediated Ca²⁺ entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5-fluorouracil. J Cell Mol Med. 2017;21:904–15. [DOI] [PubMed] [PMC]

28.

Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011;28:813–22. [DOI] [PubMed]

29.

Elzamzamy OM, Penner R, Hazlehurst LA. The role of TRPC1 in modulating cancer progression. Cells. 2020;9:388. [DOI]

30.

Santoni G, Maggi F, Morelli MB, Santoni M, Marinelli O. Transient receptor potential cation channels in cancer Therapy. Med Sci. 2019;7:108. [DOI]

31.

Peters AA, Milevskiy MJ, Lee WC, Curry MC, Smart CE, Saunus JM, et al. The calcium pump plasma membrane Ca²⁺-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. Sci Rep. 2016;6:25505. [DOI] [PubMed] [PMC]

32.

Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca²⁺-ATPase gene transcription. Circ Res. 2000;86:8–14. [DOI] [PubMed]

33.

Das P N, Pedruzzi G, Bairagi N, Chatterjee S. Coupling calcium dynamics and mitochondrial bioenergetic: an in silico study to simulate cardiomyocyte dysfunction. Mol Biosyst. 2016;12:806–17. [DOI] [PubMed]

34.

Croisier H, Tan X, Perez-Zoghbi JF, Sanderson MJ, Sneyd J, Brook BS, et al. Activation of store-operated calcium entry in airway smooth muscle cells: insight from a mathematical model. PloS one. 2013;8:e69598. [DOI] [PubMed] [PMC]

35.

Mirzakhalili E, Epureanu BI, Gourgou E. A mathematical and computational model of the calcium dynamics in Caenorhabditis elegans ASH sensory neuron. PloS one. 2018;13:e0201302. [DOI] [PubMed] [PMC]

36.

Liou J, Fivaz M, Inoue T, Meyer T. Live-cell imaging reveals sequential oligomerization and local plasma membrane targeting of stromal interaction molecule 1 after Ca²⁺ store depletion. Proc Natl Acad Sci U S A. 2007;104:9301–6. [DOI] [PubMed] [PMC]

37.

Luik RM, Wang B, Prakriya M, Wu MM, Lewis RS. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature. 2008;454:538–42. [DOI] [PubMed] [PMC]

38.

Goldbeter A, Dupont G, Berridge MJ. Minimal model for signal-induced Ca²⁺ oscillations and for their frequency encoding through protein phosphorylation. Proc Natl Acad Sci U S A. 1990;87:1461–5. [DOI] [PubMed] [PMC]

39.

Houart G, Dupont G, Goldbeter A. Bursting, chaos and birhythmicity originating from self-modulation of the inositol 1, 4, 5-trisphosphate signal in a model for intracellular Ca²⁺ oscillations. Bull Math Biol. 1999;61:507–30. [DOI] [PubMed]

40.

Breitwieser GE. Extracellular calcium as an integrator of tissue function. Int J Biochem Cell Biol. 2008;40:1467–80. [DOI] [PubMed] [PMC]

41.

Putney JW Jr. A model for receptor-regulated calcium entry. Cell Calcium. 1986;7:1–12. [DOI] [PubMed]

42.

Lewis RS. Store-operated calcium channels: new perspectives on mechanism and function. Cold Spring Harb Perspect Biol. 2011;3:a003970. [DOI] [PubMed] [PMC]

43.

Helton JC, Davis FJ, Johnson JD. A comparison of uncertainty and sensitivity analysis results obtained with random and Latin hypercube sampling. Reliab Eng Syst Saf. 2005;89:305–30. [DOI]

44.

Marino S, Hogue IB, Ray CJ, Kirschner DE. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biology. 2008;254:178–96. [DOI]

45.

Hamby DM. A comparison of sensitivity analysis techniques. Health Phys. 1995;68:195–204. [DOI] [PubMed]

46.

Thiele JC, Kurth W, Grimm V. Facilitating parameter estimation and sensitivity analysis of agent-based models: a cookbook using NetLogo and R. J Artif Soc Soc Simul. 2014;17:11. [DOI]

47.

Marino S, Kirschner DE. A multi-compartment hybrid computational model predicts key roles for dendritic cells in tuberculosis infection. Computation (Basel). 2016;4:39. [DOI] [PubMed] [PMC]

48.

Pedruzzi G, Rao KV, Chatterjee S. Mathematical model of mycobacterium-host interaction describes physiology of persistence. J Theor Biol. 2015;376:105–17. [DOI] [PubMed]

49.

Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, et al. Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290:448–56. [DOI] [PubMed] [PMC]

50.

Zhang P, Liu X, Li H, Chen Z, Yao X, Jin J, et al. TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPK/mTOR pathway. Sci Rep. 2017;7:3158. [DOI] [PubMed] [PMC]

51.

O’Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets. 2006;6:365–84. [DOI] [PubMed]

52.

Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34:378–90. [DOI] [PubMed]

53.

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–72. [DOI] [PubMed] [PMC]

54.

Tian C, Du L, Zhou Y, Li M. Store-operated CRAC channel inhibitors: opportunities and challenges. Future Med Chem. 2016;8:817–32. [DOI] [PubMed] [PMC]

55.

Ander BP, Hurtado C, Raposo CS, Maddaford TG, Deniset JF, Hryshko LV, et al. Differential sensitivities of the NCX1.1 and NCX1.3 isoforms of the Na⁺-Ca²⁺ exchanger to α-linolenic acid. Cardiovasc Res. 2007;73:395–403. [DOI] [PubMed]

56.

Lytton J, Westlin M., Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 1991;266:17067–71. [PubMed]

57.

Umemura M, Baljinnyam E, Feske S, De Lorenzo MS, Xie LH, Feng X, et al. Store-operated Ca²⁺ entry (SOCE) regulates melanoma proliferation and cell migration. PloS one. 2014;9:e89292. [DOI] [PubMed] [PMC]

58.

Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene. 2005;24:4765–77. [DOI] [PubMed]

59.

Zimmermann M, Arachchige-Don AS, Donaldson MS, Dallapiazza RF, Cowan CE, Horne MC. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin. J Biol Chem. 2012;287:22838–53. [DOI] [PubMed] [PMC]

60.

Tanwar J, Motiani RK. Role of SOCE architects STIM and Orai proteins in Cell Death. Cell Calcium. 2018;69:19–27. [DOI] [PubMed]

61.

Xu M, Seas A, Kiyani M, Ji KSY, Bell HN. A temporal examination of calcium signaling in cancer-from tumorigenesis, to immune evasion, and metastasis. Cell Biosci. 2018;8:25. [DOI] [PubMed] [PMC]

62.

Papp B, Brouland JP, Arbabian A, Gélébart P, Kovács T, Bobe R, et al. Endoplasmic reticulum calcium pumps and cancer cell differentiation. Biomolecules. 2012;2:165–86. [DOI] [PubMed] [PMC]

63.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14:72–80. [DOI] [PubMed]

64.

Brouwer IA, Katan MB, Zock PL. Dietary α-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. J Nutr. 2004;134:919–22. [DOI] [PubMed]

65.

Zuccolo E, Laforenza U, Ferulli F, Pellavio G, Scarpellino G, Tanzi M, et al. Stim and Orai mediate constitutive Ca²⁺ entry and control endoplasmic reticulum Ca²⁺ refilling in primary cultures of colorectal carcinoma cells. Oncotarget. 2018;9:31098–119. [DOI] [PubMed] [PMC]

66.

Holowka D, Korzeniowski MK, Bryant KL, Baird B. Polyunsaturated fatty acids inhibit stimulated coupling between the ER Ca²⁺ sensor STIM1 and the Ca²⁺ channel protein Orai1 in a process that correlates with inhibition of stimulated STIM1 oligomerization. Biochim Biophys Acta. 2014;1841:1210–6. [DOI] [PubMed] [PMC]

67.

Wang LS, Huang YW, Liu S, Yan P, Lin YC. Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue. BMC Cancer. 2008;8:208. [DOI] [PubMed] [PMC]

68.

Wen L, Liang C, Chen E, Chen W, Liang F, Zhi X, et al. Regulation of multi-drug resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Sci Rep. 2016;6:23269. [DOI] [PubMed] [PMC]